Arrow LionHeart LVAD Trial Progress Supports 13% Stock Gain In February
This article was originally published in The Gray Sheet
Executive Summary
Continued clinical progress in the development of Arrow's LionHeart left ventricular assist device (LVAD) as a destination therapy helped sustain a 13.2% advance in the firm's stock price in February to $45.73